Halozyme Therapeutics Q3 2023 Adj EPS $0.75 Beats $0.73 Estimate, Sales $216.03M Miss $222.63M Estimate
Portfolio Pulse from totan@benzinga.com
Halozyme Therapeutics reported Q3 2023 earnings of $0.75 per share, beating the analyst consensus estimate of $0.73 by 2.74%. However, the company's quarterly sales of $216.03 million missed the analyst consensus estimate of $222.63 million by 2.96%. This represents a 1.35% increase in earnings and a 3.38% increase in sales compared to the same period last year.
November 06, 2023 | 9:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Halozyme Therapeutics' Q3 2023 earnings beat estimates but sales missed, which could lead to mixed market reactions.
Halozyme Therapeutics reported better-than-expected earnings but lower-than-expected sales for Q3 2023. This mixed performance could lead to uncertainty among investors, potentially causing volatility in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100